Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma
| Autor: | Mattia D’Agostino, Giulia Gazzera, Giusy Cetani, Sara Bringhen, Mario Boccadoro, Francesca Gay |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
PD-L1 medicine.medical_specialty Combination therapy medicine.drug_class Antineoplastic Agents Monoclonal antibody Biochemistry Antibodies 03 medical and health sciences 0302 clinical medicine Antineoplastic Agents Immunological Internal medicine Drug Discovery PD-1 Monoclonal Antineoplastic Combined Chemotherapy Protocols medicine Humans Immunologic Factors Elotuzumab Multiple myeloma (MM) Multiple myeloma 030304 developmental biology Pharmacology Isatuximab 0303 health sciences business.industry SLAMF7 Organic Chemistry Daratumumab Antibodies Monoclonal CD38 Checkpoint blockade therapy (CBT) Monoclonal antibodies (mAbs) Combined Modality Therapy Multiple Myeloma medicine.disease Blockade Immunological 030220 oncology & carcinogenesis Molecular Medicine business medicine.drug |
| Popis: | Background: Survival of multiple myeloma patients has considerably improved in the last decades thanks to the introduction of many new drugs, including immunomodulatory agents, proteasome inhibitors and, more recently, monoclonal antibodies. Methods: We analyzed the most recent literature focusing on the clinical and pharmacologic aspects of monoclonal antibody-based therapies in multiple myeloma, including monoclonal antibodies directed against plasma cell antigens, as well as checkpoint blockade therapy directed against immune inhibitory molecules, used as single agents or in combination therapy. Results: Anti-CD38 monoclonal antibodies including daratumumab, isatuximab and MOR202 have shown outstanding results in relapsed and/or refractory multiple myeloma patients. The addition of daratumumab to bortezomib-dexamethasone or lenalidomidedexamethasone substantially improved patients’ outcome in this patient population. The anti- SLAMF7 molecule elotuzumab in combination with lenalidomide-dexamethasone showed to be superior to lenalidomide-dexamethasone alone, without adding meaningful toxicity. Checkpoint blockade therapy in combination with immunomodulatory agents produced objective responses in more than 50% of treated patients. However, this combination was also associated with an increase in toxicity and a thorough safety evaluation is currently ongoing. Conclusion: Monoclonal antibodies are reshaping the standard of care for multiple myeloma and ongoing trials will help physicians to optimize their use in order to further improve patients’ outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|